On September 24, 2025 Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation and immunology (I&I), reported it will present a late-breaking mini oral presentation on initial Phase 2 clinical results for invikafusp alfa monotherapy in tissue-agnostic, TMB-H/MSI-H solid tumors at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting taking place October 17-21, 2025, in Berlin, Germany (Press release, Marengo Therapeutics, SEP 24, 2025, View Source [SID1234656206]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Title: STARt-001: Initial Phase 2 clinical activity of invikafusp alfa, a first-in-class T cell receptor (TCR) β-chain-targeted bispecific antibody as monotherapy in patients with antigen-rich solid tumors resistant to immune checkpoint blockade (ICB)
Conference: ESMO (Free ESMO Whitepaper) Annual Meeting 2025
Abstract Number: LBA55
Session Title: Mini oral session: Investigational immunotherapy
Session Date and Time: Friday, October 17, 2025, 14:00 – 15:30
Session Room: Nuremberg Auditorium
Presenter: Antione Italiano, M.D., Ph.D. (Institut Bergonié, France)